CytoMed Therapeutics Ltd (GDTC) income statement
GDTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 31, 2026Score 4/30
$0.77−0.06 (-6.87%)
Close on Nov 19, 2026Market cap $9.14MP/E –Yield –
CytoMed Therapeutics Ltd income statement
Ratios
Latest available, balances at Dec 31, 2025
Profitability, FY2025
- Gross margin
- –
- Operating margin
- –
- Net margin
- -1227.1%
- Return on equity, FY2025
- -51.3%
Financial strength
- Current ratio
- 5.17
- Debt to equity
- 0.06
- Debt to assets
- 5.1%
- Cash to current liabilities
- 295.5%
Valuation
- P/E ratio
- –
- Price to sales
- 36.31
- Price to book
- 1.80
- Dividend yield
- –
See a number that looks wrong?